| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 08/04/2023 | 41.7% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/30/2023 | 41.7% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/05/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 05/02/2023 | 21.46% | Jefferies | → $30 | Assumes | → Buy |
| 04/19/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 02/24/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 02/08/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 01/05/2023 | 41.7% | Needham | $34 → $35 | Maintains | Buy |
| 11/04/2022 | 37.65% | Needham | $36 → $34 | Maintains | Buy |
| 08/08/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/06/2022 | 45.75% | Needham | $34 → $36 | Maintains | Buy |
| 02/22/2022 | 70.04% | Piper Sandler | $36 → $42 | Maintains | Overweight |
| 02/15/2022 | 17.41% | HC Wainwright & Co. | $26 → $29 | Maintains | Buy |
| 02/15/2022 | 37.65% | Needham | $28 → $34 | Maintains | Buy |
| 11/15/2021 | 13.36% | Needham | $26 → $28 | Maintains | Buy |
| 11/05/2021 | 5.26% | Needham | $32 → $26 | Maintains | Buy |
| 08/06/2021 | -10.93% | Cantor Fitzgerald | $30 → $22 | Downgrades | Overweight → Neutral |
| 08/06/2021 | 29.55% | Needham | $34 → $32 | Maintains | Buy |
| 08/06/2021 | 13.36% | HC Wainwright & Co. | $33 → $28 | Maintains | Buy |
| 01/11/2021 | 33.6% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 11/09/2020 | 17.41% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 07/14/2020 | -67.61% | BWS Financial | → $8 | Initiates Coverage On | → Sell |
| 05/27/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/08/2020 | 45.75% | Needham | $38 → $36 | Maintains | Buy |
| 02/12/2020 | 41.7% | Piper Sandler | $27 → $35 | Maintains | Overweight |
| 02/07/2020 | 21.46% | Cantor Fitzgerald | $24 → $30 | Maintains | Overweight |
| 02/07/2020 | 53.85% | Needham | $36 → $38 | Maintains | Buy |
| 01/08/2020 | 45.75% | Needham | $28 → $36 | Maintains | Hold |
| 08/08/2019 | -2.83% | Cantor Fitzgerald | $35 → $24 | Reiterates | → Overweight |
| 05/03/2019 | -6.88% | HC Wainwright & Co. | → $23 | Assumes | → Buy |
| 04/12/2019 | — | Janney Montgomery Scott | Assumes | → Buy | |
| 03/20/2019 | -10.93% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 08/09/2018 | 41.7% | Cantor Fitzgerald | $40 → $35 | Maintains | Overweight |
What is the target price for Collegium Pharmaceutical (COLL)?
The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $0.00 expecting COLL to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?
The latest analyst rating for Collegium Pharmaceutical (NASDAQ: COLL) was provided by HC Wainwright & Co., and Collegium Pharmaceutical reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?
While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Collegium Pharmaceutical (COLL) is trading at is $24.70, which is out of the analyst's predicted range.